linvoseltamab for relapsed/refractory multiple myeloma: updates on linker-mm1 from aacr 2024
Published 5 months ago • 348 plays • Length 16:32Download video MP4
Download video MP3
Similar videos
-
6:17
linvoseltamab for relapsed/refractory multiple myeloma: ims 2023 results with madhav dhodapkar, md
-
1:33
updates from the linker-mm1 study: linvoseltamab in r/r multiple myeloma
-
4:00
updates from linker-mm1: safety and efficacy of linvoseltamab in patients with r/r multiple myeloma
-
8:13
linker-mm1 study: linvoseltamab (regn5458) in relapsed/refractory myeloma | hans lee, md | asco 2023
-
3:35
linvoseltamab efficacy in high-risk rrmm: linker-mm1 study | attaya suvannasankha, md | ims 2024
-
10:57
linker-mm1 study: linvoseltamab (regn5458) in patients with rr multiple myeloma | asco 2023
-
1:23
dr lentzsch on results for linvoseltamab in heavily pretreated r/r myeloma
-
3:12
updated results of the linker-mm1 trial: linvoseltamab in r/r multiple myeloma
-
5:15
linker-mm1: linvoseltamab in patients with r/r multiple myeloma
-
6:19
linvoseltamab for rr multiple myeloma: deep, durable responses at 14-month follow-up (linker-mm1)
-
1:25
safety and efficacy of linvoseltamab for patients with r/r multiple myeloma
-
5:37
linvoseltamab in patients with relapsed/refractory myeloma | suzanne lentzsch md, phd | eha 2024
-
46:10
pursuing deeper responses with linvoseltamab in newly diagnosed multiple myeloma patients
-
8:15
linvoseltamab | therapies on the horizon #myeloma
-
1:47
insights into the efficacy of linvoseltamab in the treatment of r/r multiple myeloma
-
4:45
a first-in-human trial of linvoseltamab (regn5458) in r/r myeloma: updated phase i data
-
3:06
results of a phase 1 clinical trial of belantamab mafadotin in rrmm | shebli atrash, md | ims 2024
-
8:36
alnuctamab, a bcma x cd3 t-cell engager, in pts with relapsed/refractory multiple myeloma
-
1:23
association of sbcma with measures of disease burden & response to linvoseltamab in r/r myeloma